Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/61838
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings |
Autor: | Ocio, Enrique M. CSIC ORCID ; Mateos, Maria Victoria; Maiso, Patricia; Pandiella, Atanasio CSIC ORCID CVN ; San Miguel, Jesús F. CSIC ORCID | Fecha de publicación: | 2008 | Editor: | Elsevier | Citación: | Lancet Oncology 9(12): 1157-1165 (2008) | Resumen: | The outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide, lenalidomide, and bortezomib. Nevertheless, most patients still relapse and, therefore, drugs with new mechanisms of action are urgently needed to overcome this resistance. In this Review, we discuss some of the new targeted therapeutic strategies under assessment in preclinical and clinical studies in multiple myeloma. Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents. © 2008 Elsevier Ltd. All rights reserved. | URI: | http://hdl.handle.net/10261/61838 | DOI: | 10.1016/S1470-2045(08)70304-8 | Identificadores: | doi: 10.1016/S1470-2045(08)70304-8 issn: 1470-2045 e-issn: 1474-5488 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
111
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
100
checked on 29-feb-2024
Page view(s)
343
checked on 24-abr-2024
Download(s)
137
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.